🔬 Latest pharma industry updates 👇

🤝 AbbVie will acquire Apogee Therapeutics for $10.9B, adding immunology assets for atopic dermatitis and asthma.

👁️ Ollin Biosciences raised $330M Series B to move bispecific retinal antibody OLN324 into global Phase 3 trials.

🤝 Novartis partnered with Antares in a potential $1.9B oncology discovery deal targeting historically hard-to-drug cancer proteins using Antares’ small-molecule discovery platform.

🔬 Definium Therapeutics’s lysergide oral dissolving tablet met its Phase 3 depression endpoint, significantly reducing MADRS scores versus placebo.

🤝 Eli Lilly and Company partnered with BioArctic in an $800M neurodegeneration deal, combining BioArctic’s BrainTransporter blood-brain-barrier technology with an undisclosed Lilly drug candidate.

🔁 REGENXBIO will resubmit its gene therapy after FDA backtracked on another rejection.

🚨 The Bundibugyo Ebola outbreak in DRC exceeded 1,000 confirmed cases and 254 deaths, with overwhelmed treatment centers and 78 infected healthcare workers exposing surveillance gaps.

💰 Osanni Bio raised $190M Series B to fund its platform model, advancing ophthalmology and cardiology programs to proof of concept.

🤝 Eli Lilly and Company expanded its China dealmaking with Abbisko in a potential $1.9B collaboration covering multiple oncology targets.

🏭 KBI Biopharma launched a rebate program offering up to $500,000 development and manufacturing credit for promising new drug candidates.

🧴 Quoin Pharmaceuticals received conditional FDA acceptance of QYLEKI as the brand name for QRX003, its topical therapy candidate for life-threatening genetic skin disease Netherton syndrome.

🧫 Two neuromyelitis optica patients remain in remission 15 years after donor stem-cell transplants, suggesting a durable immune reset after all standard treatments had failed.

💊 Eli Lilly and Company’s oral GLP-1 orforglipron could launch in China between late 2026 and early 2027, with Alibaba and JD Health partnerships supporting commercialization.

🏛️ BIO International Convention panelists warned that U.S. federal funding cuts and restrictive immigration policies risk accelerating China’s rise from biotech innovator to global pharma competitor.

🤝 Merck Group will acquire Bio-Techne for $11.3B, expanding its life sciences tools, protein analysis, spatial biology, diagnostics, and cell and gene therapy capabilities.

🏥 The Trump administration is choosing between Jeff Vacirca and Heidi Overton for FDA commissioner after Makary’s resignation and a broader wave of agency leadership departures.

🤧 Intercept fund launched with investor like Stripe and Anthropic with $500M to develop broad respiratory antiviral treatments, aiming to protect against multiple viruses behind common infections like colds and flu.

----------

🤝 I’ll be attending BOS in Basel starting June 30th, happy to meet there!